|
| Index | - | P/E | - | EPS (ttm) | -1.85 | Insider Own | 10.61% | Shs Outstand | 43.64M | Perf Week | -0.71% |
| Market Cap | 124.12M | Forward P/E | - | EPS next Y | -2.44 | Insider Trans | 0.00% | Shs Float | 17.58M | Perf Month | -23.29% |
| Income | -73.20M | PEG | - | EPS next Q | -0.67 | Inst Own | 19.40% | Short Float | 0.43% | Perf Quarter | -48.53% |
| Sales | 10.20M | P/S | 12.17 | EPS this Y | -50.50% | Inst Trans | -0.14% | Short Ratio | 1.87 | Perf Half Y | -67.78% |
| Book/sh | 3.59 | P/B | 0.78 | EPS next Y | -41.90% | ROA | -50.40% | Target Price | 24.69 | Perf Year | -77.95% |
| Cash/sh | 3.93 | P/C | 0.71 | EPS next 5Y | - | ROE | -167.80% | 52W Range | 2.76 - 20.98 | Perf YTD | -65.30% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | -45.10% | 52W High | -86.65% | Beta | - |
| Dividend % | - | Quick Ratio | 6.20 | Sales past 5Y | - | Gross Margin | - | 52W Low | 1.63% | ATR | 0.18 |
| Employees | 259 | Current Ratio | 6.20 | Sales Q/Q | 1026.20% | Oper. Margin | - | RSI (14) | 25.36 | Volatility | 4.66% 6.11% |
| Optionable | No | Debt/Eq | 0.05 | EPS Q/Q | -643.80% | Profit Margin | - | Rel Volume | 0.71 | Prev Close | 2.82 |
| Shortable | Yes | LT Debt/Eq | 0.02 | Earnings | Mar 31 BMO | Payout | - | Avg Volume | 40.77K | Price | 2.80 |
| Recom | 1.70 | SMA20 | -10.53% | SMA50 | -21.87% | SMA200 | -67.99% | Volume | 29,143 | Change | -0.71% |
 |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite